{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T23:08:20Z","timestamp":1767136100583,"version":"build-2238731810"},"update-to":[{"DOI":"10.1002\/14651858.cd012065","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2016,12,6]],"date-time":"2016-12-06T00:00:00Z","timestamp":1480982400000}}],"reference-count":73,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd012065.pub2","type":"journal-article","created":{"date-parts":[[2016,12,6]],"date-time":"2016-12-06T10:25:12Z","timestamp":1481019912000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Topiramate versus carbamazepine monotherapy for epilepsy: an individual participant data review"],"prefix":"10.1002","author":[{"given":"Sarah J","family":"Nevitt","sequence":"first","affiliation":[{"name":"University of Liverpool; Department of Biostatistics; Block F, Waterhouse Building 1-5 Brownlow Hill Liverpool UK L69 3GL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Sudell","sequence":"additional","affiliation":[{"name":"The University of Liverpool; Department of Biostatistics; Liverpool UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catrin","family":"Tudur Smith","sequence":"additional","affiliation":[{"name":"University of Liverpool; Department of Biostatistics; Block F, Waterhouse Building 1-5 Brownlow Hill Liverpool UK L69 3GL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony G","family":"Marson","sequence":"additional","affiliation":[{"name":"Institute of Translational Medicine, University of Liverpool; Department of Molecular and Clinical Pharmacology; Clinical Sciences Centre for Research and Education, Lower Lane Fazakerley Liverpool Merseyside UK L9 7LJ"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,12,6]]},"reference":[{"issue":"Suppl 6","key":"10.1002\/14651858.CD012065.pub2-BIB0001|cit1","first-page":"274-5, Abstract","article-title":"Response to topiramate (TPM), carbamazepine (CBZ) or valproate (VPA) by seizure type in newly diagnosed epilepsy","volume":"46","author":"Ben-Menachem","year":"2005","journal-title":"Epilepsia"},{"issue":"Suppl 7","key":"10.1002\/14651858.CD012065.pub2-BIB0002|cit2","first-page":"139-40, Abstrac","article-title":"Topiramate (TPM) vs carbamazepine (CBZ) and valproate (VPA) in newly diagnosed epilepsy: effectiveness according to seizure type","volume":"45","author":"Edwards","year":"2004","journal-title":"Epilepsia"},{"issue":"Suppl 9","key":"10.1002\/14651858.CD012065.pub2-BIB0003|cit3","first-page":"270, Abstract n","article-title":"100 mg\/day topiramate as the initial target dose in newly diagnosed epilepsy","volume":"44","author":"Privitera","year":"2003","journal-title":"Epilepsia"},{"issue":"3","key":"10.1002\/14651858.CD012065.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1034\/j.1600-0404.2003.00093.x","article-title":"Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy","volume":"107","author":"Privitera","year":"2003","journal-title":"Acta Neurologica Scandinavica"},{"issue":"Suppl Florence","key":"10.1002\/14651858.CD012065.pub2-BIB0005|cit5","first-page":"138","article-title":"Topiramate EPMN-105 Study Group. Monotherapy in newly diagnosed epilepsy: topiramate vs investigator choice of carbamazepine or valproate [abstract]","volume":"41","author":"Privitera","year":"2000","journal-title":"Epilepsia"},{"issue":"Suppl 7","key":"10.1002\/14651858.CD012065.pub2-BIB0006|cit6","first-page":"93-4, Abstract","article-title":"Topiramate vs. investigator choice of carbamazepine or valproate as monotherapy in newly diagnosed epilepsy","volume":"41","author":"Privitera","year":"2000","journal-title":"Epilepsia"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD012065.pub2-BIB0007|cit7","first-page":"82, Abstract no","article-title":"Topiramate in newly diagnosed epilepsy: 100 mg\/day as initial target dose.","volume":"44","author":"Sander","year":"2003","journal-title":"Epilepsia"},{"issue":"2","key":"10.1002\/14651858.CD012065.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1177\/08830738040190020901","article-title":"Topiramate, carbamazepine, and valproate monotherapy: double-blind comparison in children with newly diagnosed epilepsy","volume":"19","author":"Wheless","year":"2004","journal-title":"Journal of Child Neurology"},{"issue":"8 Suppl 3","key":"10.1002\/14651858.CD012065.pub2-BIB0009|cit9","first-page":"A234-5, Abstrac","article-title":"Topiramate, carbamazepine, and valproate in children with newly diagnosed epilepsy: a unique trial design","volume":"56","author":"Wheless","year":"2001","journal-title":"Neurology"},{"issue":"3","key":"10.1002\/14651858.CD012065.pub2-BIB0010|cit10","first-page":"201","article-title":"A randomised open trial comparing monotherapy with topiramate versus carbamazepine in the treatment of paediatric patients with recently diagnosed epilepsy","volume":"39","author":"Resendiz-Aparicio","year":"2004","journal-title":"Revista de Neurologia"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD012065.pub2-BIB0011|cit11","first-page":"272","article-title":"Carbamazepine versus gabapentin, lamotrigine, oxcarbazepine and topiramate for epilepsy: results from arm A of the SANAD trial","volume":"47","author":"Marson","year":"2006","journal-title":"Epilepsia"},{"issue":"9566","key":"10.1002\/14651858.CD012065.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S0140-6736(07)60460-7","article-title":"The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"},{"issue":"37","key":"10.1002\/14651858.CD012065.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"iii-iv, ix-x, 1","DOI":"10.3310\/hta11370","article-title":"A randomised controlled trial examining the longer-term outcomes of standard versus new antiepileptic drugs. The SANAD trial","volume":"11","author":"Marson","year":"2007","journal-title":"Health Technology Assessment"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD012065.pub2-BIB0014|cit14","first-page":"138, Abstract n","article-title":"A multicenter, randomized, open-labeled, clinical study to evaluate the effect on cognitive and behavioral function of topiramate compared with carbamazepine as monotherapy in children with benign rolandic epilepsy","volume":"47","author":"Kang","year":"2006","journal-title":"Epilepsia"},{"issue":"9","key":"10.1002\/14651858.CD012065.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1111\/j.1528-1167.2007.01160.x","article-title":"The effects on cognitive function and behavioural problems of topiramate compared to carbamazepine as monotherapy for children with benign rolandic epilepsy","volume":"48","author":"Kang","year":"2007","journal-title":"Epilepsia"},{"issue":"Suppl 7","key":"10.1002\/14651858.CD012065.pub2-BIB0016|cit16","first-page":"322-3, Abstract","article-title":"Low-dose topiramate compared with carbamazepine in treating benign rolandic epilepsy","volume":"45","author":"Lim","year":"2004","journal-title":"Epilepsia"},{"issue":"4","key":"10.1002\/14651858.CD012065.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/j.1528-1157.1999.tb00748.x","article-title":"The incidence of epilepsy and unprovoked seizures in multiethnic, urban health maintenance organizations","volume":"40","author":"Annegers","year":"1999","journal-title":"Epilepsia"},{"issue":"7","key":"10.1002\/14651858.CD012065.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1111\/epi.12605","article-title":"An unknown quantity-the worldwide prevalence of epilepsy","volume":"55","author":"Bell","year":"2014","journal-title":"Epilepsia"},{"issue":"3","key":"10.1002\/14651858.CD012065.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1056\/NEJM199601183340308","article-title":"Antiepileptic drugs","volume":"334","author":"Brodie","year":"1996","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"10.1002\/14651858.CD012065.pub2-BIB0020|cit20","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010236.pub2","article-title":"Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child","author":"Bromley","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8968","key":"10.1002\/14651858.CD012065.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0140-6736(95)91208-8","article-title":"Remission of epilepsy: results from the National General Practice Study of Epilepsy","volume":"346","author":"Cockerell","year":"1995","journal-title":"Lancet"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012065.pub2-BIB0022|cit22","first-page":"123","article-title":"Selective effects of topiramate on sustained repetitive firing and spontaneous bursting in cultured hippocampal neurons","volume":"34","author":"Coulter","year":"1993","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD012065.pub2-BIB0023|cit23","unstructured":"Microsoft Microsoft Excel 2010"},{"issue":"4","key":"10.1002\/14651858.CD012065.pub2-BIB0024|cit24","first-page":"203","article-title":"Appendix C: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new onset epilepsy: Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society","volume":"13","author":"French","year":"2007","journal-title":"CONTINUUM Lifelong Learning in Neurology"},{"issue":"2","key":"10.1002\/14651858.CD012065.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1212\/01.WNL.0000048200.12663.BC","article-title":"A dose-comparison trial of topiramate as monotherapy in recently diagnosed partial epilepsy","volume":"60","author":"Gilliam","year":"2003","journal-title":"Neurology"},{"issue":"9995","key":"10.1002\/14651858.CD012065.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S0140-6736(15)60692-4","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013","volume":"386","author":"Global Burden of Disease Study 2013 Collaborators","year":"2015","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012065.pub2-BIB0027|cit27","unstructured":"GRADE Working Group, McMaster University GRADEPro Version 3.6 for Windows 2004"},{"issue":"3","key":"10.1002\/14651858.CD012065.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1528-1157.1993.tb02586.x","article-title":"Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota 1935-1984","volume":"34","author":"Hauser","year":"1993","journal-title":"Epilepsia"},{"issue":"7414","key":"10.1002\/14651858.CD012065.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD012065.pub2-BIB0030|cit30","unstructured":"Higgins JPT Green S editor(s) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"5","key":"10.1002\/14651858.CD012065.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1212\/01.wnl.0000252807.38124.a3","article-title":"How common are the \"common\" neurologic disorders?","volume":"68","author":"Hirtz","year":"2007","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD012065.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1212\/01.wnl.0000318293.28278.33","article-title":"Topiramate in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register","volume":"71","author":"Hunt","year":"2008","journal-title":"Neurology"},{"issue":"7","key":"10.1002\/14651858.CD012065.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/j.1528-1157.1998.tb01167.x","article-title":"Considerations on designing clinical trials to evaluate the place of new antiepileptic drugs in the treatment of newly diagnosed and chronic patients with epilepsy","volume":"39","author":"ILAE Commission on Antiepileptic Drugs","year":"1998","journal-title":"Epilepsia"},{"issue":"7","key":"10.1002\/14651858.CD012065.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/j.1528-1167.2006.00585.x","article-title":"ILAE treatment guidelines: evidence based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes","volume":"47","author":"Glauser","year":"2006","journal-title":"Epilepsia"},{"issue":"3","key":"10.1002\/14651858.CD012065.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1528-1157.1983.tb04893.x","article-title":"Natural history of epileptic seizures","volume":"24","author":"Juul-Jenson","year":"1983","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD012065.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"c365","DOI":"10.1136\/bmj.c365","article-title":"The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews","volume":"340","author":"Kirkham","year":"2010","journal-title":"BMJ"},{"issue":"5","key":"10.1002\/14651858.CD012065.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJM200002033420503","article-title":"Early identification of refractory epilepsy","volume":"342","author":"Kwan","year":"2000","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012065.pub2-BIB0038|cit38","unstructured":"Lefebvre C Manheimer E Glanville J Chapter 6: Searching for studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Intervention s Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"5","key":"10.1002\/14651858.CD012065.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1111\/j.1528-1157.1994.tb02549.x","article-title":"Absence seizures and carbamazepine in adults","volume":"35","author":"Liporace","year":"1994","journal-title":"Epilepsia"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012065.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1111\/j.1528-1157.1995.tb05996.x","article-title":"Antiepileptic drug mechanisms of action","volume":"36","author":"MacDonald","year":"1995","journal-title":"Epilepsia"},{"issue":"6","key":"10.1002\/14651858.CD012065.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/1531-8249(200012)48:6<833::AID-ANA3>3.0.CO;2-U","article-title":"Factors predicting prognosis of epilepsy after presentation with seizures","volume":"48","author":"MacDonald","year":"2000","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD012065.pub2-BIB0042|cit42","article-title":"Idiopathic Generalised Epilepsies: Clinical,Experimental and Genetic. Eastleigh: John Libbey and Company, 1994.","volume-title":"Idiopathic Generalised Epilepsies: Clinical, Experimental and Genetic","author":"Malfosse","year":"1994"},{"issue":"3","key":"10.1002\/14651858.CD012065.pub2-BIB0043|cit43","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001030","article-title":"Carbamazepine versus valproate monotherapy for epilepsy","author":"Marson","year":"2000","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD012065.pub2-BIB0044|cit44","first-page":"163","article-title":"Is carbamazepine safe to take during pregnancy?","volume":"58","author":"Matlow","year":"2012","journal-title":"Canadian Family Physician"},{"issue":"1","key":"10.1002\/14651858.CD012065.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eplepsyres.2008.04.022","article-title":"Pregnancy outcomes in women with epilepsy: a systematic reviews and meta-analysis of published pregnancy registries and cohorts","volume":"81","author":"Meador","year":"2008","journal-title":"Epilepsy Research"},{"issue":"2","key":"10.1002\/14651858.CD012065.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1136\/jnnp.2005.074203","article-title":"Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register","volume":"77","author":"Morrow","year":"2006","journal-title":"Journal of Neurology, Neurosurgery, and Neuropsychiatry"},{"key":"10.1002\/14651858.CD012065.pub2-BIB0047|cit47","volume-title":"Global Comparative Assessments in the Health Sector","author":"Murray","year":"1994"},{"issue":"5","key":"10.1002\/14651858.CD012065.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/j.1528-1167.2009.02481.x","article-title":"Estimation of the burden of active and life-time epilepsy: a meta-analytic approach","volume":"51","author":"Ngugi","year":"2010","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD012065.pub2-BIB0049|cit49","unstructured":"National Institute for Health and Care Excellence The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care London: National Institute for Health and Care Excellence"},{"key":"10.1002\/14651858.CD012065.pub2-BIB0050|cit50","unstructured":"Nolan SJ Sutton L Marson A Tudur Smith C Consistency of outcome and statistical reporting of time-to-event data: the impact on Cochrane Reviews and meta-analyses in epilepsy Better knowledge for better health. 21st Cochrane Colloquium; 2013 September 19-23; Quebec City, Canada Quebec City, Canada The Cochrane Collaboration 2013 114 5"},{"issue":"8","key":"10.1002\/14651858.CD012065.pub2-BIB0051|cit51","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001769.pub2","article-title":"Phenytoin versus valproate monotherapy for partial onset seizures and generalised onset tonic-clonic seizures","author":"Nolan","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD012065.pub2-BIB0052|cit52","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003615.pub3","article-title":"Oxcarbazepine versus phenytoin monotherapy for epilepsy","author":"Nolan","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD012065.pub2-BIB0053|cit53","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002217.pub2","article-title":"Phenobarbitone versus phenytoin monotherapy for partial onset seizures and generalised onset tonic-clonic seizures","author":"Nolan","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"12","key":"10.1002\/14651858.CD012065.pub2-BIB0054|cit54","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011412","article-title":"Antiepileptic drug monotherapy for epilepsy: a network meta-analysis","author":"Nolan","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD012065.pub2-BIB0055|cit55","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001904.pub2","article-title":"Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review","author":"Nolan","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD012065.pub2-BIB0056|cit56","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001911.pub2","article-title":"Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review","author":"Nolan","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD012065.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S1474-4422(05)70172-1","article-title":"Incidence of unprovoked seizures and epilepsy in Iceland and assessment of the epilepsy syndrome classification: a prospective study","volume":"4","author":"Olafsson","year":"2005","journal-title":"Lancet Neurology"},{"issue":"24","key":"10.1002\/14651858.CD012065.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"issue":"5","key":"10.1002\/14651858.CD012065.pub2-BIB0059|cit59","first-page":"756","article-title":"Frequency and voltage-dependent inhibition of type IIA Na+ channels,expressed in a mammalian cell line, by local anaesthetic,antiarrhythmic, and anticonvulsant drugs","volume":"40","author":"Ragsdale","year":"1991","journal-title":"Molecular Pharmacology"},{"key":"10.1002\/14651858.CD012065.pub2-BIB0060|cit60","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"issue":"9566","key":"10.1002\/14651858.CD012065.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/S0140-6736(07)60461-9","article-title":"The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD012065.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1136\/jnnp.61.5.433","article-title":"Epidemiology of the epilepsies","volume":"61","author":"Sander","year":"1996","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD012065.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.0013-9580.2004.455005.x","article-title":"The use of anti-epileptic drugs - principles and practice","volume":"45","author":"Sander","year":"2004","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD012065.pub2-BIB0064|cit64","first-page":"7","article-title":"Sodium valproate, phenytoin and carbamazepine as sole anticonvulsants","volume-title":"The Place of Sodium Valproate in the Treatment of Epilepsy","author":"Shakir","year":"1980"},{"issue":"11","key":"10.1002\/14651858.CD012065.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1212\/WNL.33.11.1487","article-title":"Myoclonic, atonic, and absence seizures following institution of carbamazepine therapy in children","volume":"33","author":"Shields","year":"1983","journal-title":"Neurology"},{"issue":"15","key":"10.1002\/14651858.CD012065.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1056\/NEJM198510103131503","article-title":"Exacerbation of seizures in children by carbamazepine","volume":"313","author":"Snead","year":"1985","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012065.pub2-BIB0067|cit67","unstructured":"College Station, TX: StataCorp LP StataCorp. 2015. Stata Statistical Software: Release 14 2015"},{"key":"10.1002\/14651858.CD012065.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"issue":"8","key":"10.1002\/14651858.CD012065.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1745-6215-8-34","article-title":"Multiple treatment comparisons in epilepsy monotherapy trials","volume":"5","author":"Tudur Smith","year":"2007","journal-title":"Trials"},{"issue":"11","key":"10.1002\/14651858.CD012065.pub2-BIB0070|cit70","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010224.pub2","article-title":"Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child","author":"Weston","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD012065.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0920-1211(97)00045-4","article-title":"Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold","volume":"28","author":"White","year":"1997","journal-title":"Epilepsy Research"},{"issue":"11","key":"10.1002\/14651858.CD012065.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1002\/sim.1303","article-title":"Aggregate data meta-analysis with time-to-event outcomes","volume":"21","author":"Williamson","year":"2002","journal-title":"Statistics in Medicine"},{"issue":"1","key":"10.1002\/14651858.CD012065.pub2-BIB0073|cit73","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012065","article-title":"Topiramate versus carbamazepine monotherapy for epilepsy: an individual participant data review","author":"Nolan","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"}],"updated-by":[{"DOI":"10.1002\/14651858.cd012065.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2019,6,24]],"date-time":"2019-06-24T00:00:00Z","timestamp":1561334400000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD012065.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T19:02:35Z","timestamp":1628535755000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD012065.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Epilepsy Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2016,12,6]]},"references-count":73,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd012065.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,6]]}}}